An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029 Administered Intravenously as a 30-Minute Infusion to Healthy Subjects
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Stamulumab (Primary)
- Indications Muscular dystrophies
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 30 May 2014 New trial record